OBJECTIVES: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. METHODS: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. RESULTS: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number <50 copies/mL was 4.1 months (95% CI 3.5-4.6) in non-coinfected patients and 3.9 months (95% CI 3.3-4.5) in coinfected patients (hazard ratio 1.039, 95% CI 0.761-1.418, P = 0.766, log-rank test). The risk of developing new grade 3-4 hepatic adverse events was significantly higher in coinfected patients (hazard ratio 1.779, 95% CI 1.123-2.817, P = 0.009). The two groups of coinfected and non-coinfected patients had similar rates of interruption of any baseline drug (hazard ratio 1.075, 95% CI 0.649-1.781, P = 0.776) and of raltegravir (hazard ratio 1.520, 95% CI 0.671-3.447, P = 0.311). Few AIDS-defining events and deaths occurred. CONCLUSIONS: Viroimmunological response to regimens based on raltegravir and other recent anti-HIV inhibitors is not negatively affected by coinfection with HBV or HCV. Liver toxicity, either pre-existing or new, is more common in coinfected patients, but with no increased risk of treatment interruption.
OBJECTIVES: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. METHODS: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. RESULTS: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfectedpatients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number <50 copies/mL was 4.1 months (95% CI 3.5-4.6) in non-coinfectedpatients and 3.9 months (95% CI 3.3-4.5) in coinfectedpatients (hazard ratio 1.039, 95% CI 0.761-1.418, P = 0.766, log-rank test). The risk of developing new grade 3-4 hepatic adverse events was significantly higher in coinfectedpatients (hazard ratio 1.779, 95% CI 1.123-2.817, P = 0.009). The two groups of coinfected and non-coinfectedpatients had similar rates of interruption of any baseline drug (hazard ratio 1.075, 95% CI 0.649-1.781, P = 0.776) and of raltegravir (hazard ratio 1.520, 95% CI 0.671-3.447, P = 0.311). Few AIDS-defining events and deaths occurred. CONCLUSIONS: Viroimmunological response to regimens based on raltegravir and other recent anti-HIV inhibitors is not negatively affected by coinfection with HBV or HCV. Liver toxicity, either pre-existing or new, is more common in coinfectedpatients, but with no increased risk of treatment interruption.
Authors: Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Jk Rockstroh; H Teppler; J Zhao; P Sklar; Cm Harvey; Km Strohmaier; Ry Leavitt; B-Yt Nguyen Journal: HIV Med Date: 2011-05-22 Impact factor: 3.180
Authors: Juan Macías; Karin Neukam; Joaquín Portilla; José A Iribarren; Ignacio de Los Santos; Antonio Rivero; Manuel Márquez; Marcial Delgado; Francisco Téllez; Dolores Merino; Livia Giner; Miguel A von Wichmann; Juan A Pineda Journal: J Antimicrob Chemother Date: 2011-03-10 Impact factor: 5.790
Authors: Nina Weis; Bjarne O Lindhardt; Gitte Kronborg; Ann-Brit E Hansen; Alex L Laursen; Peer B Christensen; Henrik Nielsen; Axel Moller; Henrik T Sorensen; Niels Obel Journal: Clin Infect Dis Date: 2006-04-12 Impact factor: 9.079
Authors: Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren Journal: J Infect Dis Date: 2005-08-11 Impact factor: 5.226
Authors: J A Pineda; J Santos; A Rivero; L Abdel-Kader; R Palacios; A Camacho; F Lozano; J Macías Journal: J Antimicrob Chemother Date: 2008-02-14 Impact factor: 5.790
Authors: Kari Yacisin; Ivana Maida; María José Ríos; Vincent Soriano; Marina Núñez Journal: AIDS Res Hum Retroviruses Date: 2008-07 Impact factor: 2.205
Authors: Ricardo A Carmo; Mark D C Guimarães; Alexandre S Moura; Augusto M Neiva; Juliana B Versiani; Letícia V Lima; Lílian P Freitas; Manoel Otávio C Rocha Journal: Braz J Infect Dis Date: 2008-06 Impact factor: 1.949
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Lei Hua; Janet W Andersen; Eric S Daar; Marshall J Glesby; Kimberly Hollabaugh; Camlin Tierney Journal: AIDS Date: 2013-11-13 Impact factor: 4.177
Authors: Julian Alexander Portocarrero Nuñez; Juan Gonzalez-Garcia; Juan Berenguer; María Jesús Vivancos Gallego; Jose Antonio Iribarren Loyarte; Luis Metola; Enrique Bernal; Gemma Navarro; Julia Del Amo; Inmaculada Jarrín Journal: Medicine (Baltimore) Date: 2018-09 Impact factor: 1.817